by GOT | Feb 18, 2022 | News
Azurity Pharmaceuticals Announces Richard Blackburn as New CEO Woburn, Mass. – February 18, 2022 – Azurity Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing innovative medicines that meet the specific needs of underserved...
by GOT | Feb 7, 2022 | News
AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF FLEQSUVY™ (baclofen oral suspension) WOBURN, MA, February 7, 2022-Azurity Pharmaceuticals, Inc., a private specialty pharmaceutical company, focused on developing innovative products to meet the unique needs of...
by GOT | Nov 8, 2021 | News
AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF EPRONTIA™ (topiramate) oral solution The first and only FDA-approved ready-to-use liquid topiramate WOBURN, MA, November 8, 2021-Azurity Pharmaceuticals, Inc. a private specialty pharmaceutical company focused on...
by GOT | Sep 20, 2021 | News
Azurity Pharmaceuticals Completes Acquisition of Arbor Pharmaceuticals WOBURN, MA & ATLANTA, GA (September 20, 2021) – Azurity Pharmaceuticals, Inc. (“Azurity”) is pleased to announce the closing of its acquisition of Arbor Pharmaceuticals, Inc. (“Arbor”), as...
by GOT | Sep 7, 2021 | News
Azurity Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of One Lot of Firvanq® (vancomycin hydrochloride for oral solution), Vancomycin 50 mg/mL Kit, Due to a Mix-Up of the Diluent Included in the Kit Company Contact: Koral Couch 781-935-8141 x119 FOR...
Recent Comments